Form 4: Ocugen Director Kirsten Castillo Granted 151,316 Stock Options

Ocugen, Inc. director Kirsten Castillo was granted 151,316 stock options with an exercise price of $0.95, vesting over approximately one year.

Summary

• Kirsten Castillo, a Director of Ocugen, Inc. (OCGN), was granted 151,316 stock options.
• The options have an exercise price of $0.95 per share.
• The transaction date for the grant was June 5, 2025.
• These options expire on June 5, 2035.
• The options will vest upon the earlier of June 5, 2026, or Ocugen, Inc.'s next annual meeting of stockholders, contingent on Ms. Castillo's continued service.

Sentiment

Score: 6

Explanation: Slightly positive as it represents a standard compensation practice that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to Director Kirsten Castillo aligns her financial interests with those of the company's shareholders, incentivizing long-term value creation.
• The options have a 10-year expiration period (until June 5, 2035), providing a long-term incentive for the director.

Negatives

• The value of the options is contingent on the future performance of Ocugen's stock price, meaning there is no guaranteed immediate financial benefit.
• Vesting is subject to continued service, meaning the director must remain with the company to realize the benefit.

Risks

• Stock Price Volatility: The ultimate value of the options is directly tied to the future market price of Ocugen's common stock, which can be highly volatile, especially for biotech companies.
• Vesting Conditions: The options are subject to vesting conditions (continued service), and if these conditions are not met, the options may be forfeited.

Future Outlook

The options are designed to incentivize the director's long-term commitment and contribution to Ocugen's growth, with vesting tied to future service and the potential for value realization over a 10-year period.

Industry Context

The granting of stock options is a common practice in the biotechnology and pharmaceutical industries to compensate directors and executives, aligning their interests with long-term shareholder value creation, especially in companies focused on research and development with long product cycles.

Comparison to Industry Standards

• The grant of stock options as a component of director compensation is a standard practice across publicly traded companies, particularly within the biotech sector.
• Companies like Moderna (MRNA) or BioNTech (BNTX) frequently utilize equity-based compensation to attract and retain talent and align management incentives with shareholder returns.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• The grant of 151,316 stock options to Kirsten Castillo, a Director of Ocugen, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders by incentivizing long-term stock price appreciation.

Next Steps

• Vesting of the 151,316 options upon the earlier of June 5, 2026, or Ocugen, Inc.'s next annual meeting of stockholders, subject to continued service.
• Potential future exercise of the options by Kirsten Castillo if the stock price exceeds the exercise price of $0.95.

Key Dates

Keywords

Ocugen, OCGN, stock options, director compensation, SEC Form 4, beneficial ownership, equity grant, Kirsten Castillo